Plain-English translation of NCT05010564 on ClinicalTrials.gov ↗ ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing TRICAR-ALL T-cells, a type of cell therapy made from your own immune cells. Your cells are taken, grown in the laboratory, and given special instructions to recognize and attack three different targets on leukemia cells. You'll receive chemotherapy first to prepare your body, then the enhanced cells are infused back into your bloodstream.
Many young patients with aggressive or relapsed leukemia run out of treatment options with standard chemotherapy. This medication is designed to give their own immune system a more powerful way to fight back against leukemia cells that have become resistant to other treatments.
You likely qualify if…
You likely don't qualify if…
You'll start with tests including blood work, imaging, and heart function checks. Then you'll receive two chemotherapy drugs over several days to prepare your body. A few days later, the enhanced immune cells are infused into your vein over 1–20 minutes. You'll stay near the hospital for at least 4 weeks and return for many follow-up visits—including checkups at day 1, 4, 7, 10, 14, 21, 28, 56, and then at 3, 6, and 12 months, with yearly visits for up to 15 years total.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States